Anocca, headquartered in Södertälje south of Stockholm, uses gene-editing technology in the development of TCR-T cell therapies—a type of cell therapy that harnesses the natural targeting ability of T cells to identify and eliminate cancer cells.
The treatment targets mutated forms of the KRAS gene, which affect approximately 90 percent of patient...
Anocca raises SEK 440 million ahead of clinical cancer trial
Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration